Clinical Trial Update: Compassionate Use of Deferiprone for Patients With Thalassemia and Iron-Induced Heart Disease

View source ↗

Summary

Deferiprone has received approval for marketing to treat iron overload in patients with thalassemia and iron-induced heart disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Beta Thalassemia Major
• Iron Overload
• Iron-induced Cardiomyopathy

Drugs mentioned

• FERRIPROX (deferiprone)

Snippet

Sponsor: Children's Hospital of Philadelphia | Conditions: Iron Overload | Status: APPROVED_FOR_MARKETING